BioVie (BIVI)
(Real Time Quote from BATS)
$0.51 USD
+0.02 (3.70%)
Updated Apr 24, 2024 03:50 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIVI 0.51 +0.02(3.70%)
Will BIVI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BIVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIVI
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
BIVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
Other News for BIVI
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
12 Health Care Stocks Moving In Monday's After-Market Session
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
12 Health Care Stocks Moving In Monday's After-Market Session